Connexion
M'inscrire

Votre recherche

Filtres

Project précédent
Projet suivant

NECESSITY FOR LLT

Necessity for lipid lowering therapy in type 2 diabetes patients
Source : Importé depuis le centre

Référence clinicaltrials.gov: NCT00639080
Type 2 diabetes
Dyslipidemia
Source : Importé depuis le centre
Type 2 Diabetes
Recrutement fermé
Dernière modification : 2011/07/20

Population cible

Condition médicale (spécialité visée)

Choix aire thérapeutique

Type 2 Diabetes

Source : Importé depuis le centre

Profil des participants

Donnée non disponible

Critères de sélection

Critères d'inclusion

Inclusion Criteria:

* LDL \< 2.5 mmol/L and total cholesterol: HDL-cholesterol ratio \< 4.0
* Blood pressure ≤ 130/80 mmHg
* No personal or family history of CVD
* No history of proteinuria or renal failure
* Taking atorvastatin (lipitor) with a dosage ≤ 10 mg, equivalent dosages for other statins follow this requirement (Simvastatin ≤ 20 mg, pravastatin ≤ 40 mg, rosuvastatin ≤ 5 mg, fluvastatin ≤ 40 mg and lovastatin ≤ 40 mg)
* Calculated by the UKPDS Risk Engine to be low risk (risk is less than 15%) for Coronary Heart Disease (CHD), fatal CHD, stroke and fatal stroke (the UKPDS Risk Engine provides risk estimates in individuals with type 2 diabetes not known to have heart disease (1), calculating the patient's risk involves considering risk factors such as age, sex, incidence of smoking and lipid levels)

Exclusion Criteria:

* Patients who do not meet the above criteria or are not willing to participate will not be included in the study

Source : Importé depuis le centre

Thérapie ou Intervention proposée

Cohortes
Nom Condition médicale Traitement État du recrutement
Entire study population Donnée non disponible All study subjects.
  • Inconnu
  • Entire study population
    État du recrutement
    unknown
    Données à jour depuis : 20 juillet 2011

    Description de l'étude

    Résumé de l'étude

    Purpose:

    To assess prior need for lipid lowering therapy in patients with type 2 diabetes.

    Background/Hypothesis:

    At present, lipid lowering therapy, usually with a HMG-CoA reductase inhibitor or "statin", is recommended therapy for selected patients with type 2 diabetes mellitus (DM). The use of statins for primary prevention of CVD is not clear. Some primary prevention studies have found a statistically significant benefit but others have not (CARDS and ASPEN).

    Although low-density lipoprotein (LDL) has traditionally been a key marker of cardiovascular disease risk (CVD) risk and thus a guide to statin treatment, in recent years apolipoprotein B (apoB) has emerged as an independent risk factor for CVD.

    In a recent study, Tildesley H. et al. showed that in 500 patients with type 2 DM not on lipid lowering therapy there was discordance between LDL and apoB values. Specifically, it was found that among patients who fail to achieve the LDL-C target, 13% of men, 24% of women less than 50 and 13% of women greater than 50 meet the apoB target. In other words, while the LDL level would indicate treatment, the apoB level would not.

    Objectives:

    The investigators propose to measure lipid parameters during lipid lowering therapy and compare this with lipid parameters at one and two months after discontinuation of therapy in selected patients with type 2 DM at low risk for CVD. Lipid parameters to be measured include: high-density lipoprotein (HDL) - cholesterol, LDL-cholesterol, triglycerides, total cholesterol, total cholesterol: HDL-cholesterol ratio and apoB. As well, A1C will be measured.

    Source : Importé depuis le centre

    Sites

    Centres participants

      1 centres
    • ENDOCRINE RESEARCH SOCIETY

      Vancouver

      BRITISH COLUMBIA, CANADA

      Recrutement local
      État du recrutement: FERMÉ

    Dernière modification : 20 juillet 2011
    Données à jour depuis : 26 juin
    Origine des données : clinicaltrials.gov
    Référence clinicaltrials.gov: NCT00639080